Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The University Of North Texas Health Science Center AT Fort Worth maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 3 pending office actions currently requiring responses. This volume reflects the ongoing prosecution activity for the institution's research outputs.
These filings are distributed across 3 distinct examiners and 3 distinct art units. This lack of overlap suggests a range of technical subject matter within the Biotechnology & Pharmaceuticals field. Each pending matter is being reviewed in a unique administrative environment, which may lead to different timelines for each application.
AKOGYERAM II, NICHOLAS A is the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending office action. No particular examiner holds a majority of the pending cases, which distributes the risk of specific examiner tendencies across the portfolio.
The presence of 3 distinct art units indicates that the university's intellectual property spans several specialized biological disciplines. Practitioners must coordinate across the various examiners to ensure consistent claim construction. The pending action under AKOGYERAM II, NICHOLAS A represents a portion of the total active prosecution effort.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AKOGYERAM II, NICHOLAS A | 1 | 26.7% | +29.5% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17361763 | Personalized Medicine Approach for Treating Cognitive Loss | AKOGYERAM II, NICHOLAS A | 27d |
| 16312346 | Blood Test for Screening Out Amyloid and Alzheimers Disease Presence | CHERNYSHEV, OLGA N | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17361763 | Personalized Medicine Approach for Treating Cognitive Loss | AKOGYERAM II, NICHOLAS A | 27d |
| 17193907 | PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS | HANEY, AMANDA MARIE | 69d |
| 16312346 | Blood Test for Screening Out Amyloid and Alzheimers Disease Presence | CHERNYSHEV, OLGA N | 70d |
| Art Unit | Apps |
|---|---|
| 3686 | 1 |
| 1682 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17361763 | Personalized Medicine Approach for Treating Cognitive Loss | AKOGYERAM II, NICHOLAS A | 3686 | §101§112 | Non-Final OA | 27d | Pending | Jun 29, 2021 |
| 17193907 | PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS | HANEY, AMANDA MARIE | 1682 | §112DPOther | Final Rejection | 69d | Pending | Mar 05, 2021 |
| 16312346 | Blood Test for Screening Out Amyloid and Alzheimers Disease Presence | CHERNYSHEV, OLGA N | 1675 | §101§112 | Non-Final OA | 70d | Pending | Dec 21, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial